Troubleshooting, References & Sponsors

From 2006.igem.org

Revision as of 21:47, 19 October 2006 by Rtkavc (Talk | contribs)
Jump to: navigation, search
Logo-si.jpg

Line-si.jpg

Backround and Signalling Pathway Proposal & Approach Anticipated Results & Significance Troubleshooting, References & Sponsors Team members

Line-si2.jpg

Contents

Troubleshooting

Luminometry Luminiscence cannot be measured in vivo since celentrazine is decays too quickly, many parallells and controls are needed and therefor few 396-well plates are used in which pattern of transfection stimulation is very complicated.


Terms

Dominant negative protein</dt>
A protein that is mutated in way that has only one domain, that interacts only with one protein in signaling pathway (in our example) upstream but not downstream. The result is blockade of pathway.</dd>

MyD88</dt>
A protein at the beginning of our signaling pathway that transfer signal from TLR receptor to downstream proteins (IRAK4) resulting in NF-kappaB activation.</dd>

TRAF6</dt>
A protein that functions as a signalling mediator which binds to IRAK1 and transfer signal downstream and also resulting in NF-kappaB activation.</dd>

NF-kappaB</dt>
A transcription factor that function as heterodimer NF-?B dimers are usually sequestered in the cytoplasm in an inactive form by molecules of the inhibitor of NF-kappaB (I?B). Activation of NF-?B involves the phosphorylation and proteolysis of the I?B proteins, release and nuclear translocation of the NF-kappaB, resulting in activation of NF-kappaB-dependent transcription.</dd>


References


Financial support


Lek2.jpg[http://www.lek.si homepage]

Krka.jpg[http://www.krka.si homepage]



Komntarji: - Terms bi se pojavljal kot 'floating bar' (predlagal Marko)


Personal tools
Past/present/future years